One of biotech's flashiest star­tups is fi­nal­ly get­ting some com­pe­ti­tion from a pi­o­neer in a brand new field

Amir Nashat fi­nal­ly has some com­pe­ti­tion.

Near­ly two years ago, Po­laris’ man­ag­ing part­ner pulled to­geth­er $60 mil­lion and some high-pro­file ad­vi­sors to launch Dew­point Ther­a­peu­tics around a new ap­proach to bi­ol­o­gy, called bio­mol­e­c­u­lar con­den­sates. Op­er­at­ing as the on­ly biotech in the space since, they’ve land­ed big-mon­ey part­ner­ships with Bay­er and Mer­ck, more ven­ture cash and a cou­ple more mar­quee board mem­bers.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER